Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2018 Sep 5. pii: S1083-8791(18)30531-7. doi: 10.1016/j.bbmt.2018.08.029. [Epub ahead of print]

PMID:
30194027
2.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis.

Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussière-Wallet H, Cascon MJP, Verbeek M, Rambaldi A, Cornelissen JJ, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T, Kröger N.

Biol Blood Marrow Transplant. 2018 Aug 30. pii: S1083-8791(18)30528-7. doi: 10.1016/j.bbmt.2018.08.026. [Epub ahead of print]

PMID:
30172776
3.

Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:310-316. doi: 10.1016/j.lungcan.2018.07.042. Epub 2018 Aug 10.

4.

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007. Epub 2018 Jun 9.

5.

Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.

Robin M, Raj K, Chevret S, Gauthier J, de Lavallade H, Michonneau D, McLornan D, Peffault de Latour R, Potter V, Kulasekararaj A, Sicre de Fontbrune F, Pagliuca A, Yakoub-Agha I, Socié G, Mufti GJ.

Eur J Haematol. 2018 Oct;101(4):466-474. doi: 10.1111/ejh.13085.

PMID:
29714032
6.

Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantation.

Tedjaseputra A, McLornan D, McCormick J, Raj K, de Lavallade H, Potter V, Kenyon M, Pagliuca A, Marsh J, Mufti G.

Intern Med J. 2018 Apr;48(4):481-483. doi: 10.1111/imj.13762. No abstract available.

PMID:
29623981
7.

Composite biomarker panel for prediction of severity and diagnosis of acute GVHD with T-cell-depleted allogeneic stem cell transplants-single centre pilot study.

Min SS, Mehra V, Clay J, Cross GF, Douiri A, Dew T, Basu TN, Potter V, Ceesay MM, Pagliuca A, Sherwood RA, Vincent RP.

J Clin Pathol. 2017 Oct;70(10):886-890. doi: 10.1136/jclinpath-2017-204399. Epub 2017 Apr 27.

PMID:
28450387
8.

Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study.

Awan S, Crosby V, Potter V, Hennig I, Baldwin D, Ndlovu M, Paradine S, Wilcock A.

Lung Cancer. 2017 Feb;104:75-78. doi: 10.1016/j.lungcan.2016.12.010. Epub 2016 Dec 21.

PMID:
28213005
9.

Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study.

Crosby V, D'Souza C, Bristow C, Proffitt A, Hussain A, Potter V, Hennig I, O'Connor R, Baracos V, Wilcock A.

Support Care Cancer. 2017 Apr;25(4):1257-1261. doi: 10.1007/s00520-016-3518-2. Epub 2016 Dec 8.

PMID:
27933464
10.

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells.

Grimaldi F, Potter V, Perez-Abellan P, Veluchamy JP, Atif M, Grain R, Sen M, Best S, Lea N, Rice C, Pagliuca A, Mufti GJ, Marsh JCW, Barber LD.

Biol Blood Marrow Transplant. 2017 Feb;23(2):293-299. doi: 10.1016/j.bbmt.2016.11.003. Epub 2016 Nov 2.

11.

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.

Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, Potter V, Danson S, Woll PJ, Griffiths R, Nolan L, Ottensmeier C.

J Thorac Oncol. 2016 Sep;11(9):1511-21. doi: 10.1016/j.jtho.2016.05.028. Epub 2016 Jun 11.

12.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.

Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis JH, Passweg JR, Yakhoub-Agha I, Tabrizi R, Bay JO, Chevallier P, Chalandon Y, Huynh A, Cahn JY, Ljungman P, Craddock C, Lenhoff S, Russell NH, Fegueux N, Socié G, Bruno B, Meijer E, Mufti GJ, de Witte T, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1615-1620. doi: 10.1016/j.bbmt.2016.05.026. Epub 2016 Jun 3.

13.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.

Pujol JL, Vansteenkiste JF, De Pas TM, Atanackovic D, Reck M, Thomeer M, Douillard JY, Fasola G, Potter V, Taylor P, Bosquée L, Scheubel R, Jarnjak S, Debois M, de Sousa Alves P, Louahed J, Brichard VG, Lehmann FF.

J Thorac Oncol. 2015 Oct;10(10):1458-67. doi: 10.1097/JTO.0000000000000653.

14.

Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.

Lal R, Hillerdal GN, Shah RN, Crosse B, Thompson J, Nicolson M, Vikström A, Potter VA, Visseren-Grul C, Lorenzo M, D'yachkova Y, Bourayou N, Summers YJ.

Lung Cancer. 2015 Aug;89(2):154-60. doi: 10.1016/j.lungcan.2015.05.003. Epub 2015 May 12.

PMID:
26101013
15.

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

Hickish T, Cassidy J, Propper D, Chau I, Falk S, Ford H, Iveson T, Braun M, Potter V, Macpherson IR, Finnigan H, Lee C, Jones H, Harrison M.

Eur J Cancer. 2014 Dec;50(18):3136-44. doi: 10.1016/j.ejca.2014.08.008. Epub 2014 Oct 28.

PMID:
25441408
16.

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital.

Wang M, Wang W, Abeywardane A, Adikarama M, McLornan D, Raj K, de Lavallade H, Devereux S, Mufti GJ, Pagliuca A, Potter VT, Mijovic A.

Biol Blood Marrow Transplant. 2015 Jan;21(1):60-6. doi: 10.1016/j.bbmt.2014.09.009. Epub 2014 Sep 28.

17.

Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, de Lavallade H, Kenyon M, Pagliuca A, Mufti GJ, Marsh JC.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1711-6. doi: 10.1016/j.bbmt.2014.06.028. Epub 2014 Jul 10.

18.

Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma.

Noriega V, Kaur H, Devereux S, Byrne J, Marcus R, Haynes A, Yallop D, McMillan A, Ingram W, Khan A, Kenyon M, Potter V, Russell N, Mufti GJ, Pagliuca A.

Leuk Res. 2014 Jul;38(7):737-43. doi: 10.1016/j.leukres.2014.03.005. Epub 2014 Mar 18.

PMID:
24787231
19.

Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.

Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, McLornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O'Donnell P.

Biol Blood Marrow Transplant. 2014 Jun;20(6):890-5. doi: 10.1016/j.bbmt.2014.03.003. Epub 2014 Mar 18.

20.

Treatment decisions and survival for people with small-cell lung cancer.

Powell HA, Tata LJ, Baldwin DR, Potter VA, Stanley RA, Khakwani A, Hubbard RB.

Br J Cancer. 2014 Feb 18;110(4):908-15. doi: 10.1038/bjc.2013.812. Epub 2014 Jan 7.

21.

Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.

Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, de Lavallade H, Dhouri A, Marsh JC, Marcus R, Devereux S, Ho A, Pagliuca A, Mufti GJ.

Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7. doi: 10.1016/j.bbmt.2013.10.021. Epub 2013 Nov 8.

22.

Haematopoietic stem cell transplantation for acquired aplastic anaemia.

Young ME, Potter V, Kulasekararaj AG, Mufti GJ, Marsh JC.

Curr Opin Hematol. 2013 Nov;20(6):515-20. doi: 10.1097/MOH.0b013e328365af83. Review.

PMID:
24104412
23.

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.

24.

Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.

Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S, Burdaeva O, Rivera F, Samuel L, Bulavina I, Potter V, Chang YL, Lokker NA, O'Dwyer PJ.

Clin Cancer Res. 2013 May 1;19(9):2541-50. doi: 10.1158/1078-0432.CCR-13-0107. Epub 2013 Mar 26.

25.

A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.

Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA.

Mol Cancer Ther. 2013 May;12(5):809-18. doi: 10.1158/1535-7163.MCT-12-0710. Epub 2013 Feb 26.

26.

High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E.

Bhattacharjee PS, Huq TS, Potter V, Young A, Davenport IR, Graves R, Mandal TK, Clement C, McFerrin HE, Muniruzzaman S, Ireland SK, Hill JM.

PLoS One. 2012;7(12):e52152. doi: 10.1371/journal.pone.0052152. Epub 2012 Dec 19.

27.

Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.

Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ.

Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21.

28.

Myelodysplastic syndromes: who and when in the course of disease to transplant.

Mufti GJ, Potter V.

Hematology Am Soc Hematol Educ Program. 2012;2012:49-55. doi: 10.1182/asheducation-2012.1.49. Review.

PMID:
23233560
29.

Ability to regulate emotion is predicted by depressive symptoms and cognitive function in a cardiac sample.

Spitznagel MB, Potter V, Miller LA, Roberts Miller AN, Hughes J, Rosneck J, Gunstad J.

J Cardiovasc Nurs. 2013 Sep-Oct;28(5):453-9. doi: 10.1097/JCN.0b013e318256be99.

PMID:
22728775
30.

Identifying patients at risk of severe Clostridium difficile-associated disease.

Potter VA, Aravinthan A.

Br J Hosp Med (Lond). 2012 May;73(5):265-70. Review.

PMID:
22585325
31.

Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.

Nagi W, Lim ZY, Krishnamurthy P, Potter V, Tindell V, Reiff-Zall L, Abdullah A, Lea N, Kenyon M, Marsh J, Ho AY, Mufti GJ, Pagliuca A.

Leuk Res. 2011 Aug;35(8):998-1000. doi: 10.1016/j.leukres.2011.02.012. Epub 2011 Jun 24.

PMID:
21704371
32.

Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, Potter V, Koh MB, Islam MS, Russell N, Marks DI, Mufti GJ, Pagliuca A.

Blood. 2011 Aug 25;118(8):2351-7. doi: 10.1182/blood-2010-12-327536. Epub 2011 Apr 25.

33.

The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.

Li-Wan-Po A, Farndon PA, Kobayashi S, Mitsudomi T, Potter VA.

Ann Pharmacother. 2011 Feb;45(2):263-75. doi: 10.1345/aph.1P496. Review.

PMID:
21304034
34.

Structured exercise does not stabilize cognitive function in individuals with mild cognitive impairment residing in a structured living facility.

Miller LA, Spitznagel MB, Busko S, Potter V, Juvancic-Heltzel J, Istenes N, Glickman E, Gunstad J.

Int J Neurosci. 2011 Apr;121(4):218-23. doi: 10.3109/00207454.2010.546537. Epub 2011 Jan 19.

35.

Serum ghrelin is inversely associated with cognitive function in a sample of non-demented elderly.

Spitznagel MB, Benitez A, Updegraff J, Potter V, Alexander T, Glickman E, Gunstad J.

Psychiatry Clin Neurosci. 2010 Dec;64(6):608-11. doi: 10.1111/j.1440-1819.2010.02145.x. Epub 2010 Oct 28.

36.

Selective determinants of inositol 1,4,5-trisphosphate and adenophostin A interactions with type 1 inositol 1,4,5-trisphosphate receptors.

Rossi AM, Sureshan KM, Riley AM, Potter VL, Taylor CW.

Br J Pharmacol. 2010 Nov;161(5):1070-85. doi: 10.1111/j.1476-5381.2010.00947.x.

37.

Sleep and cognition in older adults with cardiovascular disease.

Kociuba C, Szabo A, Gunstad J, Spitznagel MB, Potter V, Hughes J, Waechter D, Josephson R, Rosneck J.

J Cardiovasc Nurs. 2010 Nov-Dec;25(6):497-502. doi: 10.1097/JCN.0b013e3181d2546f.

PMID:
20856133
38.

The METER: a brief, self-administered measure of health literacy.

Rawson KA, Gunstad J, Hughes J, Spitznagel MB, Potter V, Waechter D, Rosneck J.

J Gen Intern Med. 2010 Jan;25(1):67-71. doi: 10.1007/s11606-009-1158-7. Epub 2009 Nov 3.

39.

Development of brain metastases in the absence of extracranial metastases during adjuvant treatment for colon cancer.

Gossage LM, Potter V.

Clin Oncol (R Coll Radiol). 2009 Dec;21(10):786. doi: 10.1016/j.clon.2009.07.009. Epub 2009 Aug 5. No abstract available.

PMID:
19660922
40.

Raised serum urea predicts for early death in small cell lung cancer.

Winter MC, Potter VA, Woll PJ.

Clin Oncol (R Coll Radiol). 2008 Dec;20(10):745-50. doi: 10.1016/j.clon.2008.09.001. Epub 2008 Oct 8.

PMID:
18845424
41.

Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.

Saif MW, Peccerillo J, Potter V.

Cancer Chemother Pharmacol. 2009 May;63(6):1017-22. doi: 10.1007/s00280-008-0831-6. Epub 2008 Sep 10.

PMID:
18781300
42.

Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation.

Potter V, Moore J.

Rev Recent Clin Trials. 2008 May;3(2):130-8. Review.

PMID:
18474024
43.

Pulse oximetry in general practice: how would a pulse oximeter influence patient management?

Potter VA.

Eur J Gen Pract. 2007;13(4):216-20. doi: 10.1080/13814780701574762.

PMID:
18324502
44.

Patient barriers to optimal cancer pain control.

Potter VT, Wiseman CE, Dunn SM, Boyle FM.

Psychooncology. 2003 Mar;12(2):153-60.

PMID:
12619147
45.

Global bioethics with humility and responsibility.

Potter VR.

Biomed Ethics. 2000;5(2):89-93. No abstract available.

PMID:
11822423
46.

A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.

Spendlove L, Li L, Potter V, Christiansen D, Loveland BE, Durrant LG.

Eur J Immunol. 2000 Oct;30(10):2944-53.

47.

On dying with personhood: socratic death.

Potter VR.

Perspect Biol Med. 1999 Autumn;43(1):103-11. Review. No abstract available.

PMID:
10701227
48.

Fragmented ethics and "bridge bioethics".

Potter VR.

Hastings Cent Rep. 1999 Jan-Feb;29(1):38-40. Review. No abstract available.

PMID:
10052010
49.
50.

Individuals bear responsibility.

Potter VR.

Bioethics Forum. 1996 Summer;12(2):27-8. No abstract available.

PMID:
11654420

Supplemental Content

Loading ...
Support Center